Clinical trials: Mammary Cancer
TNBC, Triple Negative Breast Cancer
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
This study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for…
- Trial name
- NCT07601178
- Testing
- TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.
- Trial name
- NCT06797635
- Testing
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea and 2 more
- Volunteers
- 372 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Breast Cancer Female
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
The standard treatment for breast cancer when cancer cells were found near or within the margins of the tissue that is removed during breast surgery, is radiation of the entire chest wall.
- Conditions
- Breast Cancer, Breast Cancer Female, DCIS, Stage II Breast Cancer
- Trial name
- NCT05436808
- Testing
- Partial Chest Wall Radiation Therapy
- Where
- United States
- Sponsor
- Stony Brook University
Estrogen Receptor Positive Breast Cancer
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
To determine the safety and tolerability of orally administered hydroxychloroquine with hormonal therapy. To assess the response rate of hydroxychloroquine in combination with hormonal therapy.
- Trial name
- ABC01 (NCT02414776)
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Western Regional Medical Center
Breast Neoplasms, Ovarian Neoplasms
Outcomes of Education and Counseling for BRCA1 Testing
This study will identify how personal beliefs, values and family experiences affect a person's decision as to whether or not to be tested for changes in a gene called BRCA1 or BRCA2.
- Trial name
- NCT00001468
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Breast Cancer
Surgical and Patient Reported Outcomes in Robotic Mastectomy
Conventional nipple and/or skin-sparing mastectomy (NSM/SSM) with or without immediate reconstruction is becoming one of the mainstream surgical treatment for breast cancer and risk reducing mastectomy in recent years.
- Trial name
- NCT06335550
- Testing
- Robotic mastectomy
- Where
- Singapore
- Volunteers
- 29 people
- Sponsor
- Changi General Hospital
Breast Masses, Breast Cancer
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
Photoacoustic (PA) imaging (PAI) emergerd as a rapidly evolving biomedical imaging modality, which combines the merits of optical imaging and ultrasound (US) imaging, and has a capacity in morphological, functional and molecular…
- Conditions
- Breast Masses, Breast Cancer, Breast Cancer Treated with Neoadjuvant Chemotherapy
- Trial name
- NCT06908291
- Testing
- Multi-modal photoacoustic/ultrasonic (PA/US) imaging system
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Breast Tumors
A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions
Ultrasound is a well-established imaging modality for the evaluation of breast disease. The investigators' objective is to characterise the properties of an intravascular ultrasonographic contrast agent SonoVue (sulphur…
- Trial name
- NCT00243698
- Testing
- SonoVue (sulphur hexafluoride microbubbles)
- Where
- France
- Volunteers
- 59 people
- Sponsor
- University Hospital, Tours
Breast Carcinoma
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
This phase II trial tests whether [18F]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery.
- Trial name
- NCT05226663
- Testing
- Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
High-Risk Cancer, Locally Advanced Breast Cancer
Three Fraction Radiation to Induce Immuno-Oncologic Response
Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast…
- Trial name
- TRIO (NCT03978663)
- Testing
- Neoadjuvant radiotherapy
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Cancer, Breast Neoplasms
Rehabilitation on Equal Terms - The ReMig Study
The ReMig-study aims to increase knowledge about rehabilitation needs, the rehabilitation process of arabic-speaking migrated women with BC, to increase the prerequisites for optimized and equal cancer care.
- Trial name
- NCT05689398
- Where
- Sweden
- Volunteers
- 140 people
- Sponsor
- Lund University
Breast Cancer
Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors
Hormone therapy is used to treat women with hormone receptor-positive breast cancer and aromatase inhibitor (AI) is administered after menopause.
- Trial name
- NCT04511832
- Testing
- Diclofenac
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- China Medical University Hospital
Breast Cancer-related Subclinical Lymphedema
Subclinical Lymphedema Treatment Study
Primary Objective To compare the effectiveness of 2 treatment protocols for patients with breast cancer-related subclinical lymphedema identified through bioimpedance spectroscopy, L-dex scores Secondary Objectives To determine…
- Trial name
- SLT (NCT03292198)
- Testing
- 20-30 mmHg compression sleeve and gauntlet, Manual Lymphatic Drainage
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Mercy Research
Breast Cancer
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05654532
- Testing
- AC699
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Accutar Biotechnology Inc
HER2-positive Breast Cancer
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor…
- Trial name
- NCT05325632
- Testing
- HER-2 pulsed DC1, Trastuzumab, Pertuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Breast Cancer
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
The purpose of this study is to observe the routine clinical care of patients who have been diagnosed with breast cancer and have undergone Guardant360 testing.
- Trial name
- GRECO-B (NCT04436393)
- Testing
- Guardant360 test
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Guardant Health, Inc.
Breast Cancer Female
Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
According to the European Society of Cardiology 2022, the primary prevention of cancer therapyrelated cardiovascular toxicity during anthracycline chemotherapy include renin-angiotensin- aldosterone system blockers…
- Trial name
- NCT06703593
- Testing
- Alpha lipoic acid
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- British University In Egypt
Triple Negative Breast Cancer
Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells).
- Trial name
- PRECISION (NCT06879704)
- Testing
- Imaging assessment
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Centre Henri Becquerel
Retrospective Study
Predicting Outcomes of Breast-Conserving Surgery in Breast Cancer Patients Using the Modified 5-Item Frailty Index
Background: Breast cancer is the most common malignancy among women worldwide, with breast-conserving surgery (BCS) being a key treatment.
- Trial name
- NCT06770647
- Where
- Germany
- Volunteers
- 96,586 people
- Sponsor
- Technical University of Munich
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.